Skip to content

Home
Insights
Brochures
Careers
About us
News

Home
Insights
Brochures
Careers
About us
News

Pharma News

Highlights from the Week of 13th July 2026 - 20th July 2026 ( FDA, Approval ) FDA approves Biogen's sBLA for once-weekly LEQEMBI IQLIK SC as an initiation dose to treat early Alzheimer's disease ( FDA, Approval ) FDA grants traditional approval to Novartis' FABHALTA, that slows kidney function decline in adults with IgAN ( FDA, Approval ) Merck receives FDA approval for LIPFENDRA tablets 20 mg as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including HeFH ( FDA, Approval ) Celcuity obtains FDA approval for REVTORPYK to treat HR+, HER2- locally advanced or metastatic breast cancer Pg 1/4 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 13th July – 20th July in the world of pharma and healthcare!

July 20, 2026

Highlights from the week of 06th July - 13th July Sanofi ( FDA, Approval ) FDA approves Sanofi's Sarclisa Escena SC in combination with SOC regimens to treat multiple myeloma Pfizer ( FDA, Approval ) Pfizer gets FDA approval for PADCEV plus KEYTRUDA or KEYTRUDA QLEX as neoadjuvant and adjuvant treatment for adults with MIBC regardless of cisplatin eligibility Accord BioPharma ( FDA, Approval ) Accord BioPharma obtains FDA approval of ENNUMO for adults and pediatrics to treat the same indications as NEULASTA biosimilar Vera Therapeutics ( FDA, Accelerated Approval ) FDA gives accelerated approval to Vera Therapeutics' TRUTAKNA that treats proteinuria in adults with primary IgAN All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 06th July – 13th July in the world of pharma and healthcare!

July 13, 2026

Highlights from the Week of 29th June 2026 - 06th July 2026 ( FDA, Approval ) FDA approves Vertex's CASGEVY for expanded use to treat people aged 2 years and older with either SCD with recurrent VOCs or transfusion-dependent beta thalassemia ( FDA, Approval ) Orca Bio gets FDA approval of ORCA-T for use in chronic GVHD-free survival in the treatment of adults with hematological malignancies ( EU, Approval ) EC approves Novartis' ITVISMA for the treatment of children aged two years and older, teens and adults with 5q SMA with a bi-allelic mutation in the SMN gene ( FDA, Priority Review ) FDA provides priority review to Roche’s sBLA for ENSPRYNG as a subcutaneous therapy for the treatment of TED Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 29th June – 06th July world of pharma and healthcare!

July 6, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Investor calendar

2026 RBC Capital Markets Global Healthcare Conference Q2 2026 Earnings Conference Call July 15,2026 To July 16,2026 July 16 July 15 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of July 15,2026 To July 16,2026

July 13, 2026

Sustainability Highlights Call, Virtual July 06 2026 July 06 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of July 06,2026

July 6, 2026

J P Morgan European Healthcare Forum June 18 2026 June 18 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of June 18,2026

June 15, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Healthcare Insights

INFLAMMATORY BOWEL DISE SE IBD is an umbrella term for a group of conditions that cause swelling and inflammation of the tissues in the digestive tract Global Prevalence and Incidence Country-wise affected population Prevalence 2.4-3.1M 229.7 per 100,000 2.5-3 M Incidence Low Low with increase 0.18 M High TYPES OF IBD Crohn's disease Ulcerative colitis Crohn's disease (CD): It can affect any part of the digestive tract from mouth to anus and causes deep, tissue-layer inflammation Ulcerative colitis (UC): It affects only the colon and rectum's inner lining, causing inflammation and ulcers DIAGNOSIS Blood Test Stool Test Upper Endoscopy Colonoscopy Tissue Biopsy Imaging Studies Risk factors Causes of inflammatory Bowel Disease Medium Women face a higher risk of CD; men face a higher risk of UC Smoking affects development and severity of Crohn's Commonly diagnosed between ages 15-35 Luminal Factors Microbiome Intestinal Immune System Alterations Environmental Factor Genetic Predisposition SYMPTOMS Loss of appetite Fatigue Stomach aches and cramps Weight loss Diarrhea Blood in your stool TREATMENT Surgery Bowel resection Top-down approach Nutritional support Probiotics Biologic therapy Adalimumab & Infliximab Immunosuppressants Methotrexate, Azathioprine & Mercaptopurine Corticosteroids Budesonide, Methylprednisolone & Prednisolone 5-ASA | Antibiotics 5 ASA- Mesalamine & Sulfasalazine | Antibiotics- Ciprofloxacin & Metronidazole Step-up approach Vyuhpharma® All Rights Reserved Note: This report is generated based on publicly available data

True workplace inclusivity means supporting employees with chronic, often invisible conditions. Inflammatory Bowel Disease (IBD) affects millions of professionals worldwide, impacting daily life, energy and productivity.This World IBD Day, let’s advocate for understanding, flexible workplaces, and healthcare support. 💼💜

May 19, 2026

High blood pressure isn’t just a clinical issue; it’s a productivity and workplace wellness issue. Given that stress is a major contributor to hypertension, the 2026 theme “Controlling Hypertension Together” hits home for leadership teams everywhere. Let’s foster environments where health is as important as the bottom line. 📈❤️

May 17, 2026

On World Lupus Day, we stand in support of everyone affected by lupus — raising awareness, encouraging early diagnosis, and advocating for better care and research. 💜Together, we can help improve lives through awareness, innovation, and compassion.

May 10, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

The Pharma BI division of

Vyuhgenics Inc.

Henderson, Nevada, USA – 89014

Vyuhpharma ®, All Rights Reserved.

Sitemap

Terms of use

Connect with us

Please fill in the information below, and we'll get back to you.

Full Name

Email Address

Your Company

Contact

Your message